Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305 203 2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

BigBeardTrader Aug. 31 at 2:57 PM

$SMMT https://www.ainvest.com/news/biotech-sector-stocks-witnessing-increased-search-activity-2508/

0 · Reply

PickemDeep22 Aug. 31 at 11:59 AM

$SMMT 1 week, let the countdown begin

0 · Reply

Teluride Aug. 30 at 1:54 PM

$SMMT The Eagle doesn’t fly alone… he travels with the Chiefs. At WCLC, the fire will burn brighter — Bob, Maky, and the Eagle together. #SMMT #EagleAndChiefs #WCLC

1 · Reply

TruthBroker2 Aug. 30 at 1:33 PM

$SMMT

0 · Reply

letstalk8 Aug. 29 at 10:32 PM

$SMMT I added another 800 today

2 · Reply

Newyork_ Aug. 29 at 10:30 PM

$SMMT ✨

0 · Reply

Halbalidiya Aug. 29 at 9:32 PM

$SMMT short reiterated

1 · Reply

Addallelectric Aug. 29 at 8:28 PM

$SMMT Hope everyone loaded the ship. 🚢

0 · Reply

BigBeardTrader Aug. 29 at 8:02 PM

$SMMT This is just a coiled spring, you can feel it...the thing just wants to explode.

0 · Reply

Teluride Aug. 29 at 7:04 PM

$SMMT Akeso dances in the sun, Summit rests in the shade — the eagle reminds the tribe: don’t sleep when the hunt is shared. #SMMT #EagleKnows #TribeAwake

0 · Reply

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 17 days ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 20 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 6 weeks ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 2 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 6, 2025, 4:44 PM EDT - 3 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 8:00 AM EDT - 3 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 3 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 3 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 3 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 3 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 3 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 6:00 AM EDT - 3 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 2, 2025, 1:06 AM EDT - 4 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:20 PM EDT - 4 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

May 1, 2025, 4:09 PM EDT - 4 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Apr 28, 2025, 1:00 PM EDT - 4 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 25, 2025, 3:14 PM EDT - 4 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 2:50 PM EDT - 4 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 24, 2025, 4:15 PM EDT - 4 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 23, 2025, 3:47 PM EDT - 4 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 6:15 AM EDT - 4 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 14, 2025, 9:08 AM EDT - 4 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Mar 24, 2025, 2:17 PM EDT - 5 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 17, 2025, 4:24 PM EDT - 5 months ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Feb 24, 2025, 8:13 PM EST - 6 months ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Feb 24, 2025, 3:33 PM EST - 6 months ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 12:15 PM EST - 6 months ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 AM EST - 6 months ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Feb 24, 2025, 6:05 AM EST - 6 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:00 AM EST - 6 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Feb 18, 2025, 9:00 AM EST - 6 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Jan 18, 2025, 9:33 AM EST - 8 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 13, 2025, 6:10 PM EST - 8 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 7, 2025, 7:00 AM EST - 8 months ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 11:46 PM EST - 8 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD JANX LUNR

Dec 2, 2024, 2:10 PM EST - 9 months ago

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Nov 26, 2024, 4:15 PM EST - 9 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2024, 2:14 PM EST - 10 months ago

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

Oct 30, 2024, 1:27 PM EDT - 10 months ago

Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 10 months ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Oct 23, 2024, 4:15 PM EDT - 11 months ago

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Oct 4, 2024, 10:35 AM EDT - 11 months ago

Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track

Oct 3, 2024, 4:15 PM EDT - 11 months ago

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Sep 19, 2024, 2:33 PM EDT - 1 year ago

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

MRK

Sep 16, 2024, 6:30 AM EDT - 1 year ago

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

BigBeardTrader Aug. 31 at 2:57 PM

$SMMT https://www.ainvest.com/news/biotech-sector-stocks-witnessing-increased-search-activity-2508/

0 · Reply

PickemDeep22 Aug. 31 at 11:59 AM

$SMMT 1 week, let the countdown begin

0 · Reply

Teluride Aug. 30 at 1:54 PM

$SMMT The Eagle doesn’t fly alone… he travels with the Chiefs. At WCLC, the fire will burn brighter — Bob, Maky, and the Eagle together. #SMMT #EagleAndChiefs #WCLC

1 · Reply

TruthBroker2 Aug. 30 at 1:33 PM

$SMMT

0 · Reply

letstalk8 Aug. 29 at 10:32 PM

$SMMT I added another 800 today

2 · Reply

Newyork_ Aug. 29 at 10:30 PM

$SMMT ✨

0 · Reply

Halbalidiya Aug. 29 at 9:32 PM

$SMMT short reiterated

1 · Reply

Addallelectric Aug. 29 at 8:28 PM

$SMMT Hope everyone loaded the ship. 🚢

0 · Reply

BigBeardTrader Aug. 29 at 8:02 PM

$SMMT This is just a coiled spring, you can feel it...the thing just wants to explode.

0 · Reply

Teluride Aug. 29 at 7:04 PM

$SMMT Akeso dances in the sun, Summit rests in the shade — the eagle reminds the tribe: don’t sleep when the hunt is shared. #SMMT #EagleKnows #TribeAwake

0 · Reply

db59 Aug. 29 at 5:34 PM

$SMMT Long-term sentiment remains bullish on clinical progress; short-term weakness appears linked to profit-taking and market dynamics.

0 · Reply

WadeChambley701 Aug. 29 at 2:28 PM

$SMMT UTRX eyeing breakout structure cup and handle vibes measured move lines to .21 clearing supply then expansion window opens wide on thin float

0 · Reply

BooEmmy Aug. 29 at 2:21 PM

$SMMT will be green by eod, imho

0 · Reply

EB2224 Aug. 29 at 2:05 PM

$SMMT 🐂

0 · Reply

SmokeWagon Aug. 29 at 1:47 PM

$SMMT

0 · Reply

BigBeardTrader Aug. 29 at 1:40 PM

$SMMT I have a feeling some news will be released today that will spook these shorts.

0 · Reply

letstalk8 Aug. 29 at 1:36 PM

$SMMT Limit orders are set I would like to pick up more SMMT today!

0 · Reply

TruthBroker2 Aug. 29 at 12:03 PM

$SMMT

0 · Reply

TruthBroker2 Aug. 29 at 11:27 AM

$SMMT

0 · Reply

mikelet Aug. 29 at 11:00 AM

$CRDF $VKTX $SMMT the same behavior,small biotech, highly shorted, paid bears states nonsenses and SP dip with big great news. It looks like the trend in biotech now and I will play that game, holding until they will show their true value.

1 · Reply

BigFishLittleBish Aug. 29 at 12:25 AM

$SMMT Thoughts on this?

4 · Reply

Boom1166 Aug. 28 at 10:10 PM

$SMMT

0 · Reply

Market Cap	17.61B
Revenue (ttm)	0.00
Net Income (ttm)	-221.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,544,900
Avg Vol	3,353,214
Day's Range	N/A - N/A
Shares Out	742.85M
Stochastic %K	1%
Beta	-1.06
Analysts	Strong Sell
Price Target	$33.82